TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32824214

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich dietary pattern for eight weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet for eight weeks
Number of subjects: 0
Study: 34559684

Group type: EXPERIMENTAL
Intervention: Essential oil therapy (3% concentration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (mineral oil without essential oil)
Number of subjects: 0
Study: 32101065

Group type: EXPERIMENTAL
Intervention: LC+BDE (Laparoscopic Choledochotomy with Primary Closure)
Number of subjects: 207

Group type: COMPARATOR
Intervention: LC+ESE (Laparoscopic Cholecystectomy combined with Endoscopic Stone Extraction)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: LC+BDE
Number of subjects: 207
Study: 32588760

Group type: EXPERIMENTAL
Intervention: Immune-related prognostic signature constructed using 5 immune-associated genes (CXCL5, AZU1, NOD1, TNFRSF11B, VGF)
Number of subjects: 0
Study: 32746950

Group type: EXPERIMENTAL
Intervention: Suppression group (instructed to suppress their emotions during the film)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Suppression groups (both cultural backgrounds)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Suppression group
Number of subjects: 82
Study: 35853975

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with etomidate-remifentanil (ERD group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Etomidate-remifentanil (ER group)
Number of subjects: 180
Study: 33753363

Group type: EXPERIMENTAL
Intervention: SCRATCH Trial (standard trial off HFNC)
Number of subjects: 271
Study: 32014581

Group type: EXPERIMENTAL
Intervention: Violet LED (VL) irradiation for 30 min, twice per week for three weeks (totaling six sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10% carbamide peroxide (PC) without VL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Violet LED (VL) irradiation
Number of subjects: 30
Study: 35399071

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) group training, 8 sessions weekly (120-min/session) for 2 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Menopausal health (control group)
Number of subjects: 66
Study: 34419999

Group type: EXPERIMENTAL
Intervention: Sleep-Dep (polysomnography-monitored daytime sleep opportunity)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sleep-Ctrl (daytime sleep)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Wake-Ctrl (stay awake)
Number of subjects: 65
Study: 32839527

Group type: EXPERIMENTAL
Intervention: Minocycline 150 mg (twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34987129

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg, bid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (ACEI/ARB and β‐receptor blockers)
Number of subjects: 80
Study: 32471730

Group type: EXPERIMENTAL
Intervention: Circumferential wound retractor/protector (group B)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No circumferential wound retractor (group A)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Preoperative blood glucose levels below 200mg/dl
Number of subjects: 41
Study: 35276312

Group type: EXPERIMENTAL
Intervention: Sternal-apical (SA) pad placement
Number of subjects: 484

Group type: COMPARATOR
Intervention: Anterior-posterior (AP) pad placement
Number of subjects: 484
Study: 33849138

Group type: EXPERIMENTAL
Intervention: Usual care + music therapy for 60min
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study: 34753303

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 575

Group type: COMPARATOR
Intervention: Control group (moderate/severe strokes)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Mild strokes
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Residual flow grade
Number of subjects: 575
Study: 32278195

Group type: COMPARATOR
Intervention: Sham indoor air purification
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Filtered indoor air purification
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Personal PM2.5 exposure
Number of subjects: 29
Study: 35981956

Group type: EXPERIMENTAL
Intervention: so‐tDCS with individualized frequency
Number of subjects: 28

Group type: COMPARATOR
Intervention: so‐tDCS with standardized frequency of 0.75 Hz
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: stimulation trains of 30 seconds
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: stimulation trains of 2 minutes and 5 minutes
Number of subjects: 28
Study: 35664244

Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC): UC plus personalized letter from physician, access to individualized GWG chart, ongoing counseling with RDN.
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual Care (UC): usual written educational materials and counseling by obstetric provider.
Number of subjects: 214
Study: 36220809

Group type: EXPERIMENTAL
Intervention: Cocaine-cue video exposure
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cocaine-cues
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: TSST followed by cocaine-cue video
Number of subjects: 47

Group type: COMPARATOR
Intervention: TSST
Number of subjects: 47

Group type: COMPARATOR
Intervention: Baseline ACTH levels
Number of subjects: 47
Study: 33093340

Group type: EXPERIMENTAL
Intervention: Light group (cued by light on the PCA button)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no cues to medication availability)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Light group
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study: 32228168

Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy (ABFT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-responders to treatment
Number of subjects: 39
Study: 32681402

Group type: EXPERIMENTAL
Intervention: Computer-generated medication recommendations
Number of subjects: 24
Study: 34311713

Group type: EXPERIMENTAL
Intervention: 12-week exercise program (BLESS) with four follow-up contacts for exercise adherence
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 12-week exercise program (BLESS)
Number of subjects: 40
Study: 33009542

Group type: EXPERIMENTAL
Intervention: Gray Matters intervention (education and behavioral self-monitoring app)
Number of subjects: 146
Study: 35957202

Group type: EXPERIMENTAL
Intervention: Five weeks of piano training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 35535379

Group type: EXPERIMENTAL
Intervention: Preventing Hiesho: Intervention Program for Educating Nurses (2 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pamphlet on hiesho care
Number of subjects: 130
Study: 36053828

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (test group)
Number of subjects: 158

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 158
Study: 32002565

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA) for pulmonary vein isolation (PVI) and left atrial appendage closure (LAAC) device
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC) device
Number of subjects: 27
Study: 32171508

Group type: EXPERIMENTAL
Intervention: Kefir supplementation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Milk supplementation
Number of subjects: 28
Study: 35427993

Group type: EXPERIMENTAL
Intervention: Ampicillin (AMP; n = 17)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLAC; n = 11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (AMP and PLAC)
Number of subjects: 30
Study: 32952090

Group type: EXPERIMENTAL
Intervention: Blended learning program (e-learning and on-site training)
Number of subjects: 60
Study: 32000558

Group type: EXPERIMENTAL
Intervention: Structured physiotherapy with the workplace dialogue 'Convergence Dialogue Meeting' (CDM)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Structured physiotherapy
Number of subjects: 352
Study: 36002562

Group type: EXPERIMENTAL
Intervention: Haloperidol prescribing or de-prescribing regimen
Number of subjects: 474

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: SICU participants
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Altered level of consciousness (Feature 3)
Number of subjects: 474
Study: 33998210

Group type: EXPERIMENTAL
Intervention: CPC loaded with rhBMP‐2 combined with CPC loaded with antibiotic
Number of subjects: 80

Group type: COMPARATOR
Intervention: CPC loaded with antibiotic
Number of subjects: 80
Study: 32233554

Group type: EXPERIMENTAL
Intervention: miRNA disease signature
Number of subjects: 342
Study: 33215209

Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg/day)
Number of subjects: 527
Study: 33318110

Group type: EXPERIMENTAL
Intervention: Urban health extension programme
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Divorced women
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Women aged 45-53 years
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Private employees
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Unsatisfactory knowledge
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Perceived accessibility of health extension workers
Number of subjects: 744
Study: 35509099

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtered air (FA) exposure
Number of subjects: 0
Study: 33427317

Group type: EXPERIMENTAL
Intervention: PRIMA antibullying program with student lessons
Number of subjects: 3135

Group type: EXPERIMENTAL
Intervention: PRIMA antibullying program without student lessons
Number of subjects: 3135

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3135
Study: 32992159

Group type: EXPERIMENTAL
Intervention: Open-glottis pushing
Number of subjects: 250

Group type: COMPARATOR
Intervention: Closed-glottis pushing
Number of subjects: 250
Study: 34789542

Group type: EXPERIMENTAL
Intervention: Nicotine-containing fruit/sweet-flavoured e-liquid (blackcurrant, strawberry, vanilla, caramel)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Unflavoured e-liquid
Number of subjects: 84
Study: 33412641

Group type: EXPERIMENTAL
Intervention: A1-UV aspheric intraocular lens (IOL) implantation
Number of subjects: 42

Group type: COMPARATOR
Intervention: SN60WF type IOL implantation (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: A1-UV aspheric IOL
Number of subjects: 42

Group type: COMPARATOR
Intervention: SN60WF type IOL (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 32493662

Group type: EXPERIMENTAL
Intervention: Continuous magnesium infusion (10 mmol loading dose of magnesium sulphate followed by 3 mmol/h for up to 96 hours)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no magnesium infusion)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Continuous magnesium infusion
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study: 35209708

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Pulmonary diseases
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Cardiovascular diseases (CVD)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Musculoskeletal diseases
Number of subjects: 1092
Study: 34842831

Group type: EXPERIMENTAL
Intervention: Soft white paraffin (SWP)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Hydrogen peroxide (H2O2)
Number of subjects: 2
Study: 34432203

Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg/d, orally)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/d, orally)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Xuezhikang
Number of subjects: 90

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 90
Study: 34632426

Group type: EXPERIMENTAL
Intervention: Prophylactic azithromycin (1 g orally) once at baseline
Number of subjects: 27

Group type: COMPARATOR
Intervention: No azithromycin (control group)
Number of subjects: 27
Study: 34923216

Group type: EXPERIMENTAL
Intervention: WATSU therapy combined with land-based therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Land-based therapy (Control Group)
Number of subjects: 28
Study: 32003822

Group type: EXPERIMENTAL
Intervention: PDA (Lung Cancer Screening: Is It Right for Me?)
Number of subjects: 516

Group type: COMPARATOR
Intervention: EDU (standard educational material)
Number of subjects: 516
Study: 36113828

Group type: EXPERIMENTAL
Intervention: APCS score combined with stool DNA test
Number of subjects: 2842

Group type: COMPARATOR
Intervention: APCS score combined with FIT
Number of subjects: 2842
Study: 33926493

Group type: EXPERIMENTAL
Intervention: Mild recovered trajectory
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Severe persistent symptoms trajectory
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Recovered from severe symptoms trajectory
Number of subjects: 224
Study: 33107945

Group type: EXPERIMENTAL
Intervention: Catheter ablation combined with vein of Marshall ethanol infusion
Number of subjects: 350
Study: 35900817

Group type: EXPERIMENTAL
Intervention: Mobile diabetes self-care (MC)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: MC with personalized, bidirectional feedback from physicians (MPC)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: iCareD system satisfaction
Number of subjects: 269
Study: 34592949

Group type: EXPERIMENTAL
Intervention: Epinephrine (BOSMIN® SOLUTION 0.1%, diluted to 0.02%)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Tramazoline (TRAMAZOLIN Nasal Solution 0.118%)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Epinephrine (E)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Tramazoline (T)
Number of subjects: 197
Study: 35759281

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for headache (8 sessions)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy for PTSD (12 sessions)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Treatment per usual (Control)
Number of subjects: 193
Study: 33526042

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) Basic Life Support (BLS) course, 35 minutes duration
Number of subjects: 160

Group type: COMPARATOR
Intervention: Classic BLS course with seminar and basic skill training
Number of subjects: 160
Study: 33568368

Group type: EXPERIMENTAL
Intervention: 25 mg oral melatonin nightly for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo nightly for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 25 mg oral melatonin
Number of subjects: 40
Study: 33023498

Group type: EXPERIMENTAL
Intervention: Anti-retroviral treatment (ART)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Shorter duration of ART (≤2 years)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Younger age (16-30 years)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Age 31-45 years
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Receipt of ART at Health Center IV
Number of subjects: 414
Study: 34846278

Group type: EXPERIMENTAL
Intervention: Holistic care given in line with Levine's Conservation Model (LCM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 35426326

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) treatment
Number of subjects: 1736

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1736
Study: 34789700

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 100
Study: 32801130

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 10000
Study: 36103386

Group type: COMPARATOR
Intervention: Alfaxalone (5 mg/kg, IV) + Physiologic saline (0.5 mL, IM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Alfaxalone (5 mg/kg, IM) + Physiologic saline (0.5 mL, IM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IV)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Midazolam (0.5 mg/kg, IM) + Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IV)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Midazolam (0.5 mg/kg, IM) + Medetomidine (50 μg/kg, IM) + Alfaxalone (5 mg/kg, IM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medetomidine + Alfaxalone
Number of subjects: 72
Study: 33308198

Group type: EXPERIMENTAL
Intervention: Tailored antihypertensive medication based on mean arterial pressure/heart rate ratio
Number of subjects: 208

Group type: COMPARATOR
Intervention: Non-pharmacological standard care according to national and international guidelines
Number of subjects: 208
Study: 35708709

Group type: EXPERIMENTAL
Intervention: DDGP regimen (dexamethasone, cisplatin, gemcitabine, and pegaspargase)
Number of subjects: 80

Group type: COMPARATOR
Intervention: SMILE regimen (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide)
Number of subjects: 80
Study: 34407626

Group type: EXPERIMENTAL
Intervention: Registry participants
Number of subjects: 2056

Group type: COMPARATOR
Intervention: RCT
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Eligible patients for RCT
Number of subjects: 2056
Study: 32491956

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), 2 sessions applied to pain points with a 48-hr interval
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment, 2 sessions applied to pain points with a 48-hr interval
Number of subjects: 20
Study: 34765467

Group type: EXPERIMENTAL
Intervention: Postoperative early high-energy feeding
Number of subjects: 244
Study: 32653721

Group type: EXPERIMENTAL
Intervention: Immersive video OOPP
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard in‐person OOPP
Number of subjects: 94
Study: 35255091

Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy program (3 days a week, supervised for 4 weeks, tele-supervised for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 30
Study: 32931984

Group type: EXPERIMENTAL
Intervention: Intensive management
Number of subjects: 335
Study: 32594451

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg OD
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 300 mg OD
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg OD
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg BD
Number of subjects: 304
Study: 33404791

Group type: EXPERIMENTAL
Intervention: Automated Patient Outreach (APO) app
Number of subjects: 120

Group type: COMPARATOR
Intervention: Manual phone calls
Number of subjects: 120
Study: 32305572

Group type: EXPERIMENTAL
Intervention: 1 ng/kg LPS intravenous administration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 ng/kg LPS intravenous administration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33231278

Group type: EXPERIMENTAL
Intervention: Knee joint distraction (KJD)
Number of subjects: 51

Group type: COMPARATOR
Intervention: High tibial osteotomy (HTO)
Number of subjects: 51
Study: 36181990

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (800 IU/day) for 30 months
Number of subjects: 270
Study: 34187564

Group type: EXPERIMENTAL
Intervention: Brief weight management intervention delivered at child immunisation appointments
Number of subjects: 0
Study: 32880601

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 763

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 763
Study: 34319940

Group type: EXPERIMENTAL
Intervention: Citrulline-Malate (8 g CM + 12 g dextrose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (12 g dextrose)
Number of subjects: 19
Study: 33864847

Group type: EXPERIMENTAL
Intervention: EMPOWER 2 intervention
Number of subjects: 10
Study: 36644821

Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 133
Study: 32502730

Group type: EXPERIMENTAL
Intervention: Eccentric compression for 24 hours followed by compression stockings of 18 to 20 mm Hg for 1 week
Number of subjects: 50

Group type: COMPARATOR
Intervention: No further compression after sclerotherapy
Number of subjects: 50
Study: 35432695

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400mcg
Number of subjects: 203

Group type: COMPARATOR
Intervention: Manual vacuum aspiration
Number of subjects: 203
Study: 32584834

Group type: EXPERIMENTAL
Intervention: Low household income
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Current employment
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Longer sleeping hours
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Living with a partner
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Being overweight
Number of subjects: 637

Group type: COMPARATOR
Intervention: Overall resolution rate
Number of subjects: 637
Study: 33755862

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dual-HER2 blockade with trastuzumab plus either pertuzumab or lapatinib
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 8

Group type: COMPARATOR
Intervention: Trastuzumab emtansine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MET co-targeting
Number of subjects: 8